An Engineered Cardiac Reporter Cell Line Identifies Human Embryonic Stem Cell-Derived Myocardial Precursors

Cardiovascular Research Institute, University of California San Francisco, San Francisco, California, United States of America.
PLoS ONE (Impact Factor: 3.53). 01/2011; 6(1):e16004. DOI: 10.1371/journal.pone.0016004
Source: PubMed

ABSTRACT Unlike some organs, the heart is unable to repair itself after injury. Human embryonic stem cells (hESCs) grow and divide indefinitely while maintaining the potential to develop into many tissues of the body. As such, they provide an unprecedented opportunity to treat human diseases characterized by tissue loss. We have identified early myocardial precursors derived from hESCs (hMPs) using an α-myosin heavy chain (αMHC)-GFP reporter line. We have demonstrated by immunocytochemistry and quantitative real-time PCR (qPCR) that reporter activation is restricted to hESC-derived cardiomyocytes (CMs) differentiated in vitro, and that hMPs give rise exclusively to muscle in an in vivo teratoma formation assay. We also demonstrate that the reporter does not interfere with hESC genomic stability. Importantly, we show that hMPs give rise to atrial, ventricular and specialized conduction CM subtypes by qPCR and microelectrode array analysis. Expression profiling of hMPs over the course of differentiation implicate Wnt and transforming growth factor-β signaling pathways in CM development. The identification of hMPs using this αMHC-GFP reporter line will provide important insight into the pathways regulating human myocardial development, and may provide a novel therapeutic reagent for the treatment of cardiac disease.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Flow-cytometric isolation of cardiomyocytes from cardiomyogenic human pluripotent stem cell cultures is currently achieved through two principal routes offering differing degrees of cardiomyocyte specificity and selection. The first route is more standard and relies on combinations of positive and negative cell surface marker selection (e.g. SIRP, HCN4), but does have limitations in terms of specificity. The second route, which offers greater specificity but is admittedly labor and time intensive, and fixed to the cell line in which it is generated, relies on the insertion of fluorescent reporters in cardiac specific genes (e.g. NKX2.5 or MYH6 ). With the advent of iPSC technology, there is a need for a facile, portable and robust tool for the isolation of cardiomyocytes. Herein we show that a lentivirally-deliverable antibiotic-selectable NCX1cp-EGFP reporter, based on a highly conserved cardiac enhancer sequence in the SLC8A1(NCX1) gene, permits the isolation of progenitors of contractile cardiomyocytes from human pluripotent stem cell-derived cardiomyogenic cultures.
    Stem Cells and Development 07/2014; DOI:10.1089/scd.2014.0195 · 4.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Heart disease is the leading cause of death in the world and is likely to remain as such in the foreseeable future. There is a great deal of optimism for cardiac regenerative therapies because recent advances in stem cell technology have made it possible to derive millions of cardiomyocytes from human embryonic stem cells and induced pluripotent stem cells. These stem cell-derived cardiac cells also have an enormous potential in drug discovery, toxicology studies and fundamental cardiac physiology. Cardiomyocytes do not have well-established, specific surface markers to enable their separation from heterogeneous cultures using transient antibody labelling and traditional methods such as fluorescence activated cell sorting (FACS) or magnetic activated cell sorting (MACS). Therefore, a major obstacle in realizing their potential is the development of separation methods that are compatible with clinical applications and can isolate cardiomyocytes and specific cardiac cell subpopulations after in vitro culture in sufficient numbers, purity and quality. This review provides an overview of the present state of the art in labelled and label-free cardiomyocyte isolation, the challenges to the field and a perspective on the future of cardiac cell separation.
    11/2014; 4(11):845-867. DOI:10.1166/jbt.2014.1270
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: IntroductionPosttranscriptional control of mRNA by microRNA (miRNA) has been implicated in the regulation of diverse biologic processes from directed differentiation of stem cells through organism development. We describe a unique pathway by which miRNA regulates the specialized differentiation of cardiomyocyte (CM) subtypes.MethodsWe differentiated human embryonic stem cells (hESCs) to cardiac progenitor cells and functional CMs, and characterized the regulated expression of specific miRNAs that target transcriptional regulators of left/right ventricular-subtype specification.ResultsFrom >900 known human miRNAs in hESC-derived cardiac progenitor cells and functional CMs, a subset of differentially expressed cardiac miRNAs was identified, and in silico analysis predicted highly conserved binding sites in the 3′-untranslated regions (3′UTRs) of Hand-and-neural-crest-derivative-expressed (HAND) genes 1 and 2 that are involved in left and right ventricular development. We studied the temporal and spatial expression patterns of four miRNAs in differentiating hESCs, and found that expression of miRNA (miR)-363, miR-367, miR-181a, and miR-181c was specific for stage and site. Further analysis showed that miR-363 overexpression resulted in downregulation of HAND1 mRNA and protein levels. A dual luciferase reporter assay demonstrated functional interaction of miR-363 with the full-length 3′UTR of HAND1. Expression of anti-miR-363 in-vitro resulted in enrichment for HAND1-expressing CM subtype populations. We also showed that BMP4 treatment induced the expression of HAND2 with less effect on HAND1, whereas miR-363 overexpression selectively inhibited HAND1.ConclusionsThese data show that miR-363 negatively regulates the expression of HAND1 and suggest that suppression of miR-363 could provide a novel strategy for generating functional left-ventricular CMs.
    Stem Cell Research & Therapy 06/2014; 5(3):75. DOI:10.1186/scrt464 · 4.63 Impact Factor

Full-text (2 Sources)

Available from
May 28, 2014